0 1.20628716872229E-05 0.0020989396735787 0.00120628716872339 -0.00184163862049 -0.00395662191341267 -0.00182873134778461 0.00111581563106921
Sign Up Today X
Thanks for submitting the form.
Stockreport

OncoResponse reports data from Phase I solid tumour treatment trial [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
The multicentre, two-part, open-label, first-in-human study assessed OR502's safety, tolerability, and preliminary anti-tumour activity both as a standalone therapy and in conjunction with cemiplimab, an anti-programmed cell death protein (PD)-1, in patients with advanced solid tumours. The Part A dose-escalation phase of the trial was designed to identify the maximum-tolerated dose (MTD) or optimal dose for further evaluation. Part B, the expansion phase, treated subjects with advanced solid tumours at two separate doses of OR502 to establish the recommended Phase II dose (RP2D) and to evaluate preliminary anti-tumour activity. According to the findings, OR502 showed a safety profile, without any dose-limiting toxicity (DLT) or adverse events reported even at the maximum dose level. The treatment exhibited 'promising' early efficacy signals as a monotherapy, including two partial responses (PR) and nine cases of stable disease (SD) out of 17 subjects, with a 65% disease cont [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

OncoResponse reports data from Phase I solid tumour treatment trial [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
The multicentre, two-part, open-label, first-in-human study assessed OR502's safety, tolerability, and preliminary anti-tumour activity both as a standalone therapy and in conjunction with cemiplimab, an anti-programmed cell death protein (PD)-1, in patients with advanced solid tumours. The Part A dose-escalation phase of the trial was designed to identify the maximum-tolerated dose (MTD) or optimal dose for further evaluation. Part B, the expansion phase, treated subjects with advanced solid tumours at two separate doses of OR502 to establish the recommended Phase II dose (RP2D) and to evaluate preliminary anti-tumour activity. According to the findings, OR502 showed a safety profile, without any dose-limiting toxicity (DLT) or adverse events reported even at the maximum dose level. The treatment exhibited 'promising' early efficacy signals as a monotherapy, including two partial responses (PR) and nine cases of stable disease (SD) out of 17 subjects, with a 65% disease cont [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS